Epidemiology of methicillin-resistant staphylococcus aureus bacteremia in children

Pediatrics

Volumn 139, Issue 6, 2017, Pages

  Hamdy, Rana F ^a   Hsu, Alice J ^b   Stockmann, Chris ^c   Olson, Jared A ^d   Bryan, Matthew ^e,f   Hersh, Adam L ^c   Tamma, Pranita D ^g   Gerber, Jeffrey S ^e,f  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOXITIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; LINEZOLID; OXACILLIN; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CATHETER INFECTION; CHILD; CHILD HOSPITALIZATION; CLINICAL OUTCOME; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CRITICAL ILLNESS; DISEASE DURATION; DRUG BLOOD LEVEL; ENDOVASCULAR INFECTION; FEMALE; HUMAN; INFECTION; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT FAILURE; VASCULAR DISEASE; BACTEREMIA; BLOOD; CATHETER-RELATED INFECTIONS; CLINICAL TRIAL; COMMUNITY-ACQUIRED INFECTIONS; HOSPITALIZATION; MICROBIOLOGY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASES; RECURRENT DISEASE; STAPHYLOCOCCAL INFECTIONS; STATISTICAL MODEL; VASCULAR DISEASES;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CATHETER-RELATED INFECTIONS; CHILD; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MUSCULOSKELETAL DISEASES; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; TREATMENT FAILURE; VANCOMYCIN; VASCULAR DISEASES;

EID: 85020205737     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2017-0183     Document Type: Article

References (27)

1. Lodise TP, Drusano GL, Zasowski E, et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis. 2014;59(5): 666-675
2. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43(13): 925-942
3. Fowler VG Jr, Justice A, Moore C, et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis. 2005:40(5);695-703
4. Kaasch AJ, Barlow G, Edgeworth JD, et al; ISAC, INSTINCT, SABG, UKCIRG, and Colleagues. Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. J Infect. 2014;68(3):242-251
5. Burke RE, Halpern MS, Baron EJ, Gutierrez K. Pediatric and neonatal Staphylococcus aureus bacteremia: epidemiology, risk factors, and outcome. Infect Control Hosp Epidemiol. 2009;30(7):636-644
6. Klieger SB, Vendetti ND, Fisher BT, Gerber JS. Staphylococcus aureus bacteremia in hospitalized children: incidence and outcomes. Infect Control Hosp Epidemiol. 2015;36(5):603-605
7. Khatib R, Johnson LB, Fakih MG, et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis. 2006;38(1):7-14
8. Le Moing V, Alla F, Doco-Lecompte T, et al; VIRSTA study group. Staphylococcus aureus bloodstream infection and endocarditis-a prospective cohort study. PLoS One. 2015;10(5):e0127385
9. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60(4):788-794
10. Goldman JL, Harrison CJ, Myers AL, Jackson MA, Selvarangan R. No evidence of vancomycin minimal inhibitory concentration creep or heteroresistance identified in pediatric Staphylococcus aureus blood isolates. Pediatr Infect Dis J. 2014:33(2);216-218
11. Mason EO, Lamberth LB, Hammerman WA, Hulten KG, Versalovic J, Kaplan SL. Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005. J Clin Microbiol. 2009;47(6):1628-1630
12. Liu C, Bayer A, Cosgrove SE, et al; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-e55
13. Centers for Disease Control and Prevention. Central Line-Associated Bloodstream Infection (CLABSI) Event. Safety Manual. Atlanta, GA: Centers for Disease Contol and Prevention; 2012. Available at: www.cdc.gov/nhsn/PDFs/pscManual/4PSC-CLABScurrent.pdf
14. Kullar R, McKinnell JA, Sakoulas G. Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy. Clin Infect Dis. 2014;59(10):1455-1461
15. Hill PC, Birch M, Chambers S, et al. Prospective study of 424 cases of Staphylococcus aureus bacteraemia: determination of factors affecting incidence and mortality. Intern Med J. 2001;31(2):97-103
16. Fowler VG Jr, Boucher HW, Corey GR, et al; S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653-665
17. Y aw LK, Robinson JO, Ho KM. A comparison of long-term outcomes after meticillin-resistant and meticillinsensitive Staphylococcus aureus bacteraemia: an observational cohort study. Lancet Infect Dis. 2014;14(10):967-975
18. Khatib R, Johnson LB, Sharma M, Fakih MG, Ganga R, Riederer K. Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scand J Infect Dis. 2009;41(1):4-9
19. Welsh KJ, Abbott AN, Lewis EM, et al. Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin. J Clin Microbiol. 2010;48(3):894-899
20. Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. Pediatr Infect Dis J. 2013;32(10):1077-1079
21. Le J, Bradley JS, Murray W, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32(4):e155-e163
22. Hahn A, Frenck RW Jr, Allen-Staat M, Zou Y, Vinks AA. Evaluation of target attainment of vancomycin area under the curve in children with methicillin-resistant Staphylococcus aureus bacteremia. Ther Drug Monit. 2015;37(5):619-625
23. McNeil JC, Kok EY, Forbes AR, et al. Healthcare-associated Staphylococcus aureus bacteremia in children: evidence for reverse vancomycin creep and impact of vancomycin trough values on outcome. Pediatr Infect Dis J. 2016;35(3):263-268
24. Knoderer CA, Nichols KR, Lyon KC, Veverka MM, Wilson AC. Are elevated vancomycin serum trough concentrations achieved within the first 7 days of therapy associated with acute kidney injury in children? J Pediatric Infect Dis Soc. 2014;3(2):127-131
25. Chhim RF, Arnold SR, Lee KR. Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive Staphylococcal infections. J Pediatric Infect Dis Soc. 2013;2(3):259-262
26. Nielsen LE, Clifford RJ, Kwak Y, et al. An 11, 000-isolate same plate/same day comparison of the 3 most widely used platforms for analyzing multidrug-resistant clinical pathogens. Diagn Microbiol Infect Dis. 2015;83(2):93-98
27. Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2013;57(4):1654-1663